Clinical and echocardiographic characteristics of patients with preserved versus mid-range ejection fraction.
Ibrahim MaraiNizar AndriaLiza Grosman-RimonEvgeni HazanovWadi KinanyDiab GhanimOffer AmirShemy CarassoPublished in: The international journal of cardiovascular imaging (2020)
A wide range of ejection fraction (EF) thresholds have been used to categorize patients with heart failure (HF) with "preserved" EF. Our goal was to characterize the clinical and echocardiographic differences among patients with cardiac structural/functional alterations and mid-range EF (mrEF) (EF 40-49%) compared to preserved EF (pEF) (EF ≥ 50%), irrespective of HF. Patients with an EF ≥ 40% and echocardiographic evidence of structural alterations (left atrial enlargement and/or left ventricular hypertrophy) and/or functional alterations (evidence of diastolic dysfunction) were retrospectively selected. Patients with acute coronary syndromes and ≥ moderate left sided valvular diseases were excluded. Patients were divided according to EF to pEF group (n = 578) and mrEF (n = 86). Patients with mrEF were twice as likely to be men, had higher prevalence of hyperlipidemia, diabetes and smoking, compared to patients with pEF. History of coronary artery disease (CAD) was more frequent among mrEF (50% vs. 28%, p < 0.0001, respectively), and highest among the subgroup of patients with HF (83% vs. 35%, p < 0.0001, respectively). Patients with mrEF had increased LV mass index (131 ± 35 vs. 120 ± 26 g/m2, p < 0.001), LV end diastolic diameter (55 ± 5 vs 51 ± 3, p < 0.0001), mitral E to e' ratio (16 ± 7 vs. 14 ± 5, p = 0.001), and left atrial systolic diameter (44 ± 5 mm vs. 42 ± 4 mm, p = 0.01. respectively). Patients with mrEF demonstrated worse structural and functional echocardiographic alterations and were more likely to be men and to have CAD compared to patients with pEF.
Keyphrases
- ejection fraction
- left ventricular
- left atrial
- aortic stenosis
- mitral valve
- coronary artery disease
- atrial fibrillation
- heart failure
- cardiac resynchronization therapy
- hypertrophic cardiomyopathy
- acute myocardial infarction
- acute coronary syndrome
- cardiovascular disease
- acute heart failure
- cardiovascular events
- pulmonary hypertension
- percutaneous coronary intervention
- newly diagnosed
- metabolic syndrome
- transcatheter aortic valve replacement
- clinical trial
- oxidative stress
- randomized controlled trial
- aortic valve
- smoking cessation
- study protocol
- double blind